Evidence map›Paper›PMID 41105052›Full record

ArticleInternational journal of radiation oncology, biology, physics2026

Genomic and Transcriptomic Profiling of Radiation-Resistant, Locally Recurrent Prostate Cancer.

Beth K Neilsen, Rong Rong Huang, Luca F Valle, James A Proudfoot, Elai Davicioni, Liying Zhang, Una Ryg, Melanie Schulz-Jaavall, Joanne B Weidhaas, Milisuryani Santoso and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of radiation oncology, biology, physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Beth K NeilsenDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, California.
Rong Rong HuangDepartment of Pathology, University of California, Los Angeles, Los Angeles, California.
Luca F ValleDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, California.
James A ProudfootVeracyte Inc, San Diego, California.
Elai DavicioniVeracyte Inc, San Diego, California.
Liying ZhangDepartment of Pathology, University of California, Los Angeles, Los Angeles, California.
Una RygDivision of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.
Melanie Schulz-JaavallDepartment of Oncology, Oslo University Hospital, Oslo, Norway.
Joanne B WeidhaasDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, California.
Milisuryani SantosoDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, California.
Sophia ParmisanoDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, California.
Jeremie CalaisAhmanson Translational Theranostics Division, University of California, Los Angeles, Los Angeles, California.
Robert E ReiterDepartment of Urology, University of California, Los Angeles, Los Angeles, California.
Matthew B RettigDepartment of Medical Oncology, University of California, Los Angeles, Los Angeles, California.
Michael L SteinbergDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, California.
Anthony SiskDepartment of Pathology, University of California, Los Angeles, Los Angeles, California.
Wayne BrisbaneDepartment of Urology, University of California, Los Angeles, Los Angeles, California.
Leonard S MarksDepartment of Urology, University of California, Los Angeles, Los Angeles, California.
Paul C BoutrosDepartment of Urology, University of California, Los Angeles, Los Angeles, California.
Wolfgang H LillebyDepartment of Oncology, Oslo University Hospital, Oslo, Norway.
Amar U KishanDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, California; Department of Urology, University of California, Los Angeles, Los Angeles, California. Electronic address: aukishan@mednet.ucla.edu.

Funding

Biomedical Data Science Training Program for Precision Health EquityT15LM013976 · NLM · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ALEX BUI · 2022 to 2026
$1.9M
Reducing toxicity from prostate cancer radiotherapy through genetics and technologyR37CA292795 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Amar U Kishan · 2024 to 2026
$1.1M
NCI NIH HHS R37 CA292795NLM NIH HHS T15 LM013976
6 · The paper itself

Abstract

purposeThe biology of locally radiorecurrent prostate cancer (LRR-PCa) is poorly understood. METHODS AND MATERIALS: We sought to explore the genomic and transcriptomic landscape of LRR-PCa with targeted DNA sequencing and RNA expression analysis from 41 biopsy-proven LRR-PCa tumors from 36 unique patients who had a recurrence at a median interval of 84 months (IQR, 70-124 months). Genomic alteration frequencies and transcriptomic data were compared between the LRR-PCa cohort and treatment-naïve patients from the Cancer Genome Atlas (genomic; n = 496) and Gleason grade-at-recurrence-matched patients from the Decipher Genomics Resource for Intelligent Discovery (transcriptomic; n = 22,320).

resultsTwenty-five patients (69%) had pathologic upgrading at recurrence (17% vs 64% with Gleason grade 4-5 disease; P < .001). The LRR-PCa cohort demonstrated significantly greater single-nucleotide variations in 29 genes known to be associated with prostate cancer, including several associated with increased aggressiveness and DNA repair: FAT1 (58.5% vs 1.0%), RAD51B (36.6% vs 0.4%), POLQ (34.1% vs 1.4%), KMT2C (34.1% vs 4.9%), BRCA2 (29.3% vs 1.8%), ATRX (26.8% vs 0.8%), and BRCA1 (24.4% vs 0.4%) (Pvalues < .001 for all). The LRR-PCa cohort had a significantly higher Decipher score (median, 0.80 vs 0.66; P = .05) and demonstrated significantly greater basal subtype based on PAM50 (56% vs 20%; P < .001) and lower androgen receptor activity (61% for LRR vs 9%; P < .001).

conclusionsOverall, these results suggest that LRR-PCa has a distinct genomic and transcriptomic landscape from de novo prostate cancer. Specifically, LRR-PCa has an enrichment in SNVs in genes associated with tumor aggressiveness and/or DNA repair, has higher Decipher scores, a more basal subtype, and has transcriptomic evidence of lower androgen receptor activity and loss of tumor suppressor genes.

Indexed as

Gene Expression ProfilingNeoplasm Recurrence, LocalProstatic NeoplasmsRadiation ToleranceTranscriptomeAgedDNA RepairGenomicsHumansMaleMiddle AgedNeoplasm GradingReceptors, AndrogenReceptors, Androgen

Identifiers

PMID41105052
PMCPMC13602262

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.